

Healthcare & Life Sciences Industry Overview

TEMPERATURE-CONTROLLED PACKAGING AND THE GROWING PHARMACEUTICAL COLD CHAIN

While the pandemic put a spotlight on its complexities, the life sciences cold chain was already benefiting from long-term trends driving growth. The highly critical element of packaging is one of its most important facets and stands to benefit from this growth.

Here, we share our views on the cold chain packaging opportunity in pharmaceuticals and possible avenues of investment.

Read the article.

M&A ENVIRONMENT⁽¹⁾

There have been roughly 510 M&A transactions in the healthcare and life sciences (HCLS) industry since the beginning of 2021, worth roughly \$62 billion, compared with approximately \$222 billion for all of 2020.

Notable recent transactions include the acquisition of Rodeo Therapeutics Corporation by Amgen Inc. (NasdaqGS: AMGN); GenMark Diagnostics, Inc. (NasdaqGM: GNMK) by Roche Holding AG (SWX: ROG); and Five Prime Therapeutics, Inc. by Amgen Inc. (NasdaqGS: AMGN).

PUBLIC COMPANY PERFORMANCE (1)

Stock prices increased for many healthcare and life sciences companies during the past three months. In fact, the Harris Williams HCLS Composite Index increased 12.9%, while the S&P increased 5.8%. Notable sector increases include assisted living (increased 124.3%), acute-care hospitals (increased 30.2%), and retail pharmacy (increased 29.2%).

Industry-wide stock prices have experienced increases as a whole; the HCLS Composite Index showed an increase over the past 12 months of 83.1%. At the category level, provider-based services grew by 88.9% on average over the past 12 months, followed by payor, provider, and pharmacy support services increasing 49.2%, and products and devices stock prices increasing 43.3%. Specific stock price growth leaders over the past year include acute-care hospitals (261.1%), disease management (254.8%) and assisted living (218.2%).

INDUSTRY NEWS

Researchers in Israel were happy to get their hands on data about thousands of COVID-19 patients, including a 63-year-old father of two who was admitted to the emergency room with COVID-19 and soon recovered. It was the early days of the coronavirus pandemic and the treatments used for this patient could provide invaluable insight into the then little-understood virus. Normally, it would have been unthinkable to share sensitive medical details, such as the patient's use of Lipitor for high cholesterol, so quickly, without taking measures to safeguard his privacy. But this man wasn't real. He was a fake patient created by algorithms that take details from real-life data sets such as electronic medical records, scramble them and piece them back together to create artificial patient populations that largely mirror the real thing but don't include any real patients. "Synthetic-data technology," by creating artificial patient populations, has the potential to speed up innovations without compromising privacy. (A)


When hospitals and other facilities abruptly halted elective care roughly a year ago to help mitigate the impact of the intensifying coronavirus pandemic, the economic effects rippled across the healthcare industry. Hospitals lost billions of dollars as the lucrative procedures faded away. Smaller providers like dentist and physician offices also took large financial hits. And top medtechs, many of which are reliant on elective care to drive revenue growth, saw businesses fall. The effects were also felt by patients. Some procedures delayed or canceled were not just aesthetic surgeries but considered essential care, such as joint replacements to reduce pain or cardiac procedures that can be lifesaving. The industry and Wall Street are waiting to see when exactly surgeries return and what a comeback might look like. (B)

A cost-saving change in Medicare launched in the final days of the Trump administration will cut payments to hospitals for some surgical procedures while potentially raising costs and confusion for patients. For years, the Centers for Medicare & Medicaid Services classified 1,740 surgeries and other services so risky for older adults that Medicare would pay for them only when they were admitted to the hospital as inpatients. Under the new rule, the agency is beginning to phase out that requirement and, on January 1, 266 shoulder, spine and other musculoskeletal surgeries were crossed off what's called the "inpatient-only list." (C)



M&A Overview⁽¹⁾

Announced Healthcare & Life Sciences M&A



Healthcare & Life Sciences M&A Trends

ANNOUNCED HEALTHCARE & LIFE SCIENCES TRANSACTIONS



Announced Private Equity M&A Activity

PEG INVESTMENTS BY SEGMENT (LAST 3 YEARS)

HC&LS Industry Segment	Number of Companies
Healthcare Facilities	135
Healthcare Services	129
Healthcare Equipment	37
Pharmaceuticals	25
Healthcare Technology	49
Life Sciences Tools and Services	22
Healthcare Supplies	13
Healthcare Distributors	6
Biotechnology	17
Managed Healthcare	7

HEALTHCARE TRANSACTION HIGHLIGHTS

Announced	Target	Buyer
3/30/2021	Rodeo Therapeutics Corporation	Amgen Inc. (NasdaqGS:AMGN)
3/15/2021	GenMark Diagnostics, Inc. (NasdaqGM:GNMK)	Roche Holding AG (SWX:ROG)
3/4/2021	Five Prime Therapeutics, Inc. (NasdaqGS:FPRX)	Amgen Inc. (NasdaqGS:AMGN)
3/3/2021	Asuragen, Inc.	Bio-Techne Corporation (NasdaqGS:TECH)
3/2/2021	Resolution Bioscience, Inc.	Agilent Technologies, Inc. (NYSE:A)
2/25/2021	Pandion Therapeutics, Inc. (NasdaqGS:PAND)	Merck Sharp & Dohme Corp.
2/24/2021	PRA Health Sciences, Inc. (NasdaqGS:PRAH)	ICON Public Limited Company (NasdaqGS:ICLR)
2/17/2021	Cognate BioServices, Inc.	Charles River Laboratories International, Inc. (NYSE:CRL)


LTM DEAL STATISTIC (1)

Aggregate	Number	Median Trans	action Multiples
Value (\$bn)	of Deals	TEV/Rev	TEV/EBITDA
\$266.4	1.621	4.0x	13.5x

MEDIAN HEALTHCARE & LIFE SCIENCES TRANSACTION MULTIPLES





EG INVESTMENTS





Debt Markets Overview

Key Credit Statistics⁽¹⁾









■ Revolving Credit / Term Loan A
■ Weighted-Average Institutional

SELECT HEALTHCARE & LIFE SCIENCES DEBT OFFERINGS (2)

(by deal amount)

Date Effective	Borrower Name	Description	Amount (\$ mm)	Tranche	Rating	Spread
03/02/21	National Mentor Holdings Inc	General Purpose	\$1,500	Term Loan B	B1	L+ 375
03/12/21	DuPage Medical Group	General Purpose	\$650	Term Loan B	B2	L+ 325
03/30/21	Home Care Assistance LLC	General Purpose	\$280	Term Loan B	NR	L+ 500
03/05/21	AmeriHealth Caritas	General Purpose	\$250	Delay Draw Term Loan	NR	L+ 113
03/09/21	Stepping Stones Group	General Purpose	\$215	Term Loan	NR	L+ 625

Public Markets Overview⁽¹⁾


KEY TRADING STATISTICS

(Details begin on page 10)

Clinical Laboratories Contract Pharma Manufacturing Contract Research Organizations Disease Management Healthcare Staffing HMO - Medical Information Services Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitcal Acute-Care Hospitcal Management Ling-Term Care Physician Practice Management		mber of mpanies 2 2 6 1 3 7 9 3	\$51,557 \$21,269 \$118,348 \$1,521 \$10,859 \$718,669 \$35,394	Change in St 3 mos. 16.5% (0.3%) 9.6% 13.9% 14.3% 8.0%	ock Price 12 mos. 80.8% 42.5% 88.5% 254.8% 85.3% 45.4%	2.2x 9.8x 3.9x 3.5x	7.7x 0.0x 22.2x 10.5x 14.4x	2.2x 8.2x 3.5x 3.2x	9.0x 0.0x 18.1x 10.0x
Contract Pharma Manufacturing Contract Research Organizations Disease Management Healthcare Staffing HMO - Medical Information Services Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical Country Medical Country Medical Journal Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		2 2 6 1 3 7	\$51,557 \$21,269 \$118,348 \$1,521 \$10,859 \$718,669	16.5% (0.3%) 9.6% 13.9% 14.3%	80.8% 42.5% 88.5% 254.8% 85.3%	2.2x 9.8x 3.9x 3.5x	7.7x 0.0x 22.2x 10.5x	2.2x 8.2x 3.5x 3.2x	9.0x 0.0x 18.1x
Contract Pharma Manufacturing Contract Research Organizations Disease Management Healthcare Staffing HMO - Medical Information Services Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical Country Medical Country Medical Journal Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		2 6 1 3 7	\$21,269 \$118,348 \$1,521 \$10,859 \$718,669	(0.3%) 9.6% 13.9% 14.3%	42.5% 88.5% 254.8% 85.3%	9.8x 3.9x 3.5x	0.0x 22.2x 10.5x	8.2x 3.5x 3.2x	0.0x 18.1x
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		6 1 3 7 9	\$118,348 \$1,521 \$10,859 \$718,669	9.6% 13.9% 14.3%	88.5% 254.8% 85.3%	3.9x 3.5x	22.2x 10.5x	3.5x 3.2x	18.1x
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		1 3 7 9	\$1,521 \$10,859 \$718,669	13.9% 14.3%	254.8% 85.3%	3.5x	10.5x	3.2x	
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		3 7 9	\$10,859 \$718,669	14.3%	85.3%				10.0x
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		7	\$718,669			1.5x	14.4x	1 /lv	
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		9		8.0%	45.4%			1.44	11.6x
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		_	\$35,394		43.470	1.1x	12.5x	1.1x	13.1x
Retail Pharmacy Specialty Managed Care Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical / Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		3		(5.6%)	24.7%	4.4x	18.7x	4.0x	12.9x
Dental Products Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living			\$269,748	29.2%	26.8%	0.6x	8.1x	0.6x	12.6x
Durable Medical Equipment Life Sciences Tools Medical Devices and Products Medical Surgical / Dental Supplies & Spec Pharma and Generics Acute-Care Hospitals Assisted Living		3	\$16,983	(2.5%)	36.2%	3.3x	19.7x	4.8x	26.3x
Spec Pharma and Generics Acute-Care Hospitals Assisted Living		2	\$143,747	16.1%	52.7%	4.4x	18.7x	3.8x	15.0x
Spec Pharma and Generics Acute-Care Hospitals Assisted Living		4	\$41,148	(2.6%)	20.7%	2.7x	14.8x	2.8x	13.1x
Spec Pharma and Generics Acute-Care Hospitals Assisted Living		3	\$319,224	(2.0%)	60.9%	6.0x	18.5x	5.5x	17.0x
Spec Pharma and Generics Acute-Care Hospitals Assisted Living		11	\$1,297,955	4.4%	46.3%	6.4x	26.7x	5.4x	18.5x
Acute-Care Hospitals Assisted Living	& Distribution	6	\$102,753	12.8%	40.6%	0.3x	9.3x	0.3x	8.6x
Assisted Living		12	\$141,861	11.4%	77.3%	2.3x	10.1x	2.3x	8.3x
		3	\$133,330	30.2%	261.1%	1.3x	8.9x	1.2x	8.1x
Diagnostic Imaging Dialysis Services Home Care, Hospice and Home Infus Long-Term Care		2	\$6,975	124.3%	218.2%	2.3x	10.6x	1.9x	30.5x
Dialysis Services Home Care, Hospice and Home Infus Long-Term Care		1	\$2,328	11.1%	106.9%	2.1x	9.4x	1.9x	12.4x
Home Care, Hospice and Home Infus		3	\$60,522	(8.0%)	19.3%	2.1x	8.1x	1.9x	9.1x
Long-Term Care	ion	5	\$24,219	(11.2%)	31.2%	3.6x	24.4x	3.4x	22.6x
		2	\$7,282	23.0%	79.1%	1.8x	11.6x	2.3x	18.9x
Physician Practice Management		1	\$2,749	3.8%	118.8%	1.6x	11.8x	1.6x	12.1x
Behavioral Health / Management		5	\$25,899	0.0%	34.6%	0.9x	12.4x	1.2x	9.4x
Surgicenters / Rehabilitation		4	\$29,683	13.0%	142.6%	2.6x	12.5x	2.4x	14.6x
Payor, Provider & Pharmacy Support	: Services	36	\$1,244,348	9.7%	49.2%	1.8x	13.2x	1.6x	13.5x
Products & Devices		38	\$2,046,687	5.2%	43.3%	5.8x	20.2x	5.1x	16.6x
Provider-Based Services		26	\$292,984	7.0%	88.9%	2.2x	11.6x	2.0x	12.0x
HW HCLS Composite Index		100	\$3,584,020	12.9%	83.1%	4.2x	17.3x	3.7x	15.3x
S&P 500			·	5.8%	53.7%		·		

PUBLIC COMPANY SECTOR PERFORMANCE


(12-month % change in stock price)





Equity Markets Overview

Healthcare & Life Sciences Industry Stock Performance⁽¹⁾



TOP EQUITY OFFERINGS (2)

(by proceeds)

Closing Date	Issuer	Ticker	Transaction Type	Gross Proceeds (\$ mm)
03/31/21	Coursera, Inc.	COUR	IPO	\$519
03/26/21	Zhihu Inc.	ZH	IPO	\$523
03/26/21	Alignment Healthcare, Inc.	ALHC	IPO	\$490
03/18/21	Tuya Inc.	TUYA	IPO	\$915
03/17/21	Olo Inc.	OLO	IPO	\$450
03/11/21	Coupang, Inc.	CPNG	IPO	\$4,550
03/10/21	Roblox Corp	RBLX	IPO	\$8,950
03/03/21	Os car Health, Inc.	OSCR	IPO	\$1,445

^{1.} S&P

Company Filings

A. Comprised of public company comparables listed on pages 10-16

M&A Transactions

Announced U.S. Healthcare & Life Sciences M&A(1)

Announced	Target	Seller	Buyer	Enterprise Value (\$mm)		se Value / I EBITDA I	TM_ BIT	Private Equity Involvement
4/1/2021	Qbrexza	Dermira, Inc.	Journey Medical Corporation	\$156.5	6.5x	-	-	No
4/1/2021	Global Health Sciences, Inc.	-	Lytus Technologies Holdings Private Limited	\$1.1	-	-	-	No
4/1/2021	SarahCare Adult Day Services, Inc.	-	Innovative MedTech Inc. (OTCPK:FRHV.D)	-	-	-	-	No
4/1/2021	Hospice Care of America	-	St. Croix Hospice, LLC	-	-	-	-	No
4/1/2021	Certain operations of Windy City Cannabis	Windy City Cannabis	Parallel	\$155.0	-	-	-	No
4/1/2021	Tenex Health, Inc.	-	Trice Medical, Inc.	-	-	-	-	No
4/1/2021	Ariano Dermatology	-	Pinnacle Dermatology, LLC	-	-	-	-	No
4/1/2021	Sentage Corporation	Golub Capital LLC; Cressey & Company LP	National Dentex Corporation	-	-	-	-	Yes
4/1/2021	Los Angeles Cardiology Associates	-	PIH Health, Inc.	-	-	-	-	No
4/1/2021	SH Franchising, LLC	Altaris Capital Partners, LLC	Advocate Aurora Enterprises	-	-	-	-	Yes
4/1/2021	6 diagnostic imaging clinics located in Florida		Akumin Inc. (TSX:AKU)	\$39.0	-	-	-	No
4/1/2021	Pasco Southwest Home Health	-	The Pennant Group, Inc. (NasdagGS:PNTG)	-	-	-	-	No
3/31/2021	Healing Center, LLC	-	Verano Holdings Corp. (CNSX:VRNO)	\$110.3	-	-	-	No
3/31/2021	Southwest Pulmonary Associates L.L.P.	-	Sound Inpatient Physicians, Inc.	-	-	-	-	No
3/31/2021	Rocky Mount Family Medical Center	-	Generations Family Practice, P.A.	-	-	-	-	No
3/31/2021	Varian Biopharmaceuticals Inc.	-	Healthtech Oncology, Inc.	-	-	-	-	No
3/31/2021	The FlexPro Group, LLC		Network Partners, Inc.		-	-	-	No
3/31/2021	Assets Of Central Hospital Services Inc	Central Hospital Services Inc	Q-Centrix LLC	-	-	-	-	No
3/31/2021	Two post-acute care campuses located in Wisconsin	-	-	-	-	-	-	No
3/31/2021	Biomax Health Products, Inc.	-	Wellbeam Consumer Health LLC	-	-	-	-	No
3/30/2021	Alydia Health, Inc.	AXA Investment Managers S.A.; Avestria Ventures Management, LLC; Global Health Investment Advisors, LLC	Organon & Co.	\$240.0	-	-	-	Yes
3/30/2021	PROHealth Home Care Services, Inc.	-	Best Life Brands, LLC	-	-	-	-	No
3/30/2021	Access Physicians Management Services Organization, LLC	Health Enterprise Partners	SOC Telemed, Inc. (NasdaqGS:TLMD)	\$221.1	-	-	-	No
3/30/2021	Databound Solutions, Inc.	-	Cloudmed	-	-	-	-	No
3/30/2021	QueueDr Inc.	Clayton Associates, LLC; 500 Startups Management Co., LLC; Launchpad Digital Health LLC	Phreesia, Inc. (NYSE:PHR)	\$10.1	-	-	-	Yes
3/30/2021	Bioness Inc.	-	Bioventus Inc. (NasdaqGS:BVS)	\$110.0	2.8x	-	-	No
3/30/2021	VaccTrack Inc.	-	ProPhase Diagnostics, Inc.	-	-	-	-	No
3/30/2021	Rodeo Therapeutics Corporation	Arch Venture Partners, L.P.; Johnson & Johnson Innovation - JJDC, Inc.; WRF Capital; Accelerator Life Science Partners; AbbVie Ventures, Inc.; Alexandria Venture Investments, LLC	Amgen Inc. (NasdaqGS:AMGN)	\$721.0	-	-	-	Yes
3/30/2021	All Assets of Henry Ford Village, Inc.	Henry Ford Village, Inc.	MED Healthcare Partners LLC	\$69.0	-	-	-	No
3/30/2021	Landmark Holdings, LLC	Praesidian Capital	-	-	-	-	-	Yes
3/30/2021	Stradis Healthcare, LLC	-	Henry Schein, Inc. (NasdaqGS:HSIC)	-	-	-	-	No

M&A Transactions

Announced U.S. Healthcare & Life Sciences M&A(1)

	T	Calley	P.····	Enterprise		rise Value		Private Equity
Announced	Target	Seller	Buyer	Value (\$mm)	Sales	EBITDA	EBIT	Involvement
3/29/2021	Millendo Therapeutics, Inc. (NasdaqCM:MLND)	Adams Street Partners, LLC; Frazier	Tempest Therapeutics Inc.	-	-	-	-	Yes
		Healthcare Partners; New Enterprise						
		Associates, Inc.; Bpifrance Investissement						
		SAS; 5AM Venture Management, LLC; Great						
		Point Partners, LLC; Roche Venture Fund; Ann						
		Arbor SPARK, Investment Arm; Altitude Life Science Ventures; Business Leaders For						
		Michigan, Investment Arm; Longwood Fund;						
		Renaissance Venture Capital Management,						
		Inc.; Osage University Partners						
		inc., Osage Oniversity Faithers						
3/29/2021	Banyan Pediatric Care Centers, Inc.	-	Assisted 4 Living, Inc. (OTCPK:ASSF)	-	-	-	-	No
3/29/2021	Three New Clinics of ATI Holdings, Inc.	ATI Holdings, Inc.	Physical Rehabilitation Network, LLC	-	-	-	-	No
3/26/2021	Chelsea Otolaryngology, PLLC of Dr. William Portnoy	Dr. William Portnoy	ENT and Allergy Associates, LLP	-	-	-	-	No
3/26/2021	Montgomery Addiction Clinic, PLLC	-	AppleGate Recovery LLC	-	-	-	-	No
3/26/2021	The McGuire Group, Inc.	-	VestraCare	-	-	-	-	No
3/26/2021	Casamba LLC	ABRY Partners, LLC	Net Health Systems, Inc.	-	-	-	-	Yes
3/25/2021	The Walman Optical Company Inc.		EssilorLuxottica Société anonyme (ENXTPA:EL)	-	-	-	-	No
3/25/2021	Dropprint Genomics	Y Combinator Management LLC	Immunai Inc.	-	-	-	-	No
3/24/2021	Trapelo Health	-	NeoGenomics, Inc. (NasdaqCM:NEO)	\$65.0	-	-	-	No
3/24/2021	PWNHealth, LLC/Home Access Health Corporation	Spectrum Equity Management, L.P. BlueCross	Everly Well, Inc.	-	-	-	-	Yes
		BlueShield Venture Partners, L.P.						
3/24/2021	myNEXUS, Inc.	WindRose Health Investors, LLC	Anthem, Inc. (NYSE:ANTM)	-	-	-	-	Yes
3/24/2021	Bronx Family Eye Care, Inc.	-	Global Tech Industries Group, Inc. (OTCPK:GTII)	\$3.7	-	-	-	No
3/24/2021	Always Best Care of Chicagoland & South Suburbs	ABCSP, Inc.	-	-	-	-	-	No
3/24/2021	Mayfair Technology Limited Liability Company	-	Mettler-Toledo LLC	\$205.0	-	-	-	No
3/23/2021	Eclat Health/Hansei Solutions	-	Gulf Capital Pvt. JSC	-	-	-	-	Yes
3/23/2021	Renovacor, Inc.	Novartis Venture Funds; BioAdvance; New	Chardan Healthcare Acquisition 2 Corp.	-	-	-	-	Yes
		Leaf Venture Partners, LLC; Innogest SGR	(AMEX:CHAQ)					
		S.p.A; Broadview Ventures, Inc.; Elysia Capital						
		Limited; Acorn Bioventures; Longview						
		Ventures						
3/23/2021	Symp2Pass Inc	SmartCone Technologies Inc.	Predictmedix Inc. (CNSX:PMED)	\$4.0	2.2x	-	-	No
3/23/2021	100-unit senior housing facility in Augusta, Georgia	-	Sabra Health Care REIT, Inc. (NasdaqGS:SBRA)	-	-	-	-	No
3/23/2021	Assets of Elanco Animal Health Incorporated	Elanco Animal Health Incorporated (NYSE:ELAN)	Virbac SA (ENXTPA:VIRP)	-	-	-	-	No

What We've Been Reading

TECH | THE PEOPLE IN THIS MEDICAL RESEARCH ARE FAKE — THE INNOVATIONS ARE REAL

Researchers in Israel were happy to get their hands on data about thousands of COVID-19 patients, including a 63-year-old father of two who was admitted to the emergency room with COVID-19 and soon recovered. Normally, it would have been unthinkable to share sensitive medical details, such as the patient's use of Lipitor for high cholesterol, so quickly, without taking measures to safeguard his privacy. But this man wasn't real. He was a fake patient created by algorithms that take details from real-life data sets such as electronic medical records, scramble them and piece them back together to create artificial patient populations that largely mirror the real thing but don't include any real patients. Medical researchers and data scientists say such "synthetic" healthcare data has the potential to speed up medical innovation. The rapid digitization of health records has created troves of patient information that can be analyzed by algorithms and harnessed to improve disease-treatment models and develop new products and services. But patient information isn't easy to get because privacy laws require medical data to be stripped of names, addresses and other identifying details before it can be shared, a time-consuming process that can take months. Even those measures don't satisfy some privacy advocates, who point to studies showing that it is possible to reidentify patients even after data sets have been anonymized. Enter synthetic-data technology. "The key advantage that synthetic data offers for healthcare is a large reduction in privacy risks that have bugged numerous projects [and] to open up healthcare data for the research and development of new technologies," says Allan Tucker, a professor at Brunel University London and author of a study published in Nature in November showing the validity of using synthetic data as a substitute for real healthcare data. Read the article.

PRODUCTS & DEVICES | ALL EYES ON ELECTIVE CARE AFTER A ROLLERCOASTER YEAR FOR MEDTECH

When hospitals and other facilities abruptly halted elective care roughly a year ago to help mitigate the impact of the intensifying coronavirus pandemic, the economic effects rippled across the healthcare industry. Hospitals lost billions of dollars as the lucrative procedures faded away. Smaller providers like dentist and physician offices also took large financial hits. And top medtechs, many of which are reliant on elective care to drive revenue growth, saw businesses fall. The effects were also felt by patients. Some procedures delayed or canceled were not just aesthetic surgeries but considered essential care, such as joint replacements to reduce pain or cardiac procedures that can be lifesaving. While procedure volumes returned throughout 2020 from the lows of March and April, they fell once again in November and December, and top medtech executives warned unexpected slowdowns in the fourth quarter would likely spill into 2021. After the worse-than-expected last four months, things have recently looked up. Mayuri Shah, a partner with Bain & Company, said vaccine rollouts have been faster than expected and some regions are opening up at a faster pace than others, all contributing to an uptick in elective procedures. "The first few weeks [of 2021], were surprising in a negative way. Things were hit much more than folks anticipated," Shah said. "It's also, in the same way, picked back up more quickly than anticipated." As industry and experts look further into 2021, all eyes are on both when and how elective care comes back. Read the article.

PAYOR | UNDER NEW COST-CUTTING MEDICARE RULE, SAME SURGERY, SAME PLACE, DIFFERENT BILL

A cost-saving change in Medicare launched in the final days of the Trump administration will cut payments to hospitals for some surgical procedures while potentially raising costs and confusion for patients. For years, the Centers for Medicare & Medicaid Services classified 1,740 surgeries and other services so risky for older adults that Medicare would pay for them only when they were admitted to the hospital as inpatients. Under the new rule, the agency is beginning to phase out that requirement and, on January 1, 266 shoulder, spine and other musculoskeletal surgeries were crossed off what's called the "inpatient-only list." By the end of 2023, the list — which includes a variety of complicated procedures, including brain and heart operations — is scheduled to be gone. CMS officials said the change was designed to give patients and doctors more options and help lower costs by promoting more competition among hospitals and independent ambulatory surgical centers. But they forgot one thing. While removing the surgeries from the inpatient-only list, the government did not approve them to be performed anywhere else. So patients will still have to get the care at hospitals. But because the procedures have been reclassified, patients who have them in the hospital don't have to be considered admitted patients. Instead, they can receive services on an outpatient basis. CMS pays hospitals less for care provided to beneficiaries who are outpatients, so the new policy means the agency can pay less than it did last year for the same surgery at the same hospital and Medicare outpatients will usually pick up a bigger part of the tab. "The impetus for this is for Medicare to save money," said Dr. James Huddleston, a professor of orthopedic surgery at the Stanford University Medical Center and the chair of the American Association of Hip and Knee Surgeons' Health Policy Council. "The oldest trick in the book is to say the patients don't need to be cared for in an expensive hospital setting." But since seniors will still hav

CONTENTS

- > PUBLIC MARKETS OVERVIEW
- > EQUITY MARKETS OVERVIEW
- M&A OVERVIEW
- DEBT MARKETS OVERVIEW
- > HEALTHCARE & LIFE SCIENCES PUBLIC COMPARABLES
- M&A TRANSACTIONS

CONTACTS

Turner Bredrup

Senior Advisor <u>tbredrup@harriswilliams.com</u> +1 (804) 915-0110

James Clark

Managing Director <u>iclark@harriswilliams.com</u> +1 (804) 915-0119

Andy Dixon

Managing Director adixon@harriswilliams.com +1 (415) 217-3419

Paul Hepper

Managing Director phepper@harriswilliams.com +1 (804) 932-1326

Whit Knier

Managing Director wknier@harriswilliams.com +1 (804) 932-1321

Cheairs Porter

Managing Director cporter@harriswilliams.com +1 (804) 915-0130

Geoff Smith

Managing Director gsmith@harriswilliams.com +1 (804) 915-0195

Nick Owens

nowens@harriswilliams.com +1 (415) 217-3453

Tyler Bradshaw

Director tbradshaw@harriswilliams.com +1 (804) 887-6121

Stephan Doering

Director sdoering@harriswilliams.com +49 69 7593 7153

Charles Busch

Vice President cbusch@harriswilliams.com +1 (804) 887-6093

Andrew Hoft

Vice President <u>ahoft@harriswilliams.com</u> +1 (415) 265-6139

Michael Mahoney

Vice President <u>mmahoney@harriswilliams.com</u> +1 (415) 217-3452

Nathan Robertson

Vice President <u>nrobertson@harriswilliams.com</u> +1 (804) 887-6135

Lucas Scholl

Vice President <u>Ischoll@harriswilliams.com</u> +1 (415) 416-0766

Taylor Will

Vice President twill@harriswilliams.com +1 (804) 887-6068



Payor, Provider & Pharmacy Support Services⁽¹⁾

Company Name	3/31/2021	Stock l % Chai			Week Low	Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)		Twelve Mo (LTM) EBITDA	onths EBIT	LTM Period	Latest FYE Date	Forwar Revenue	d Twelve ! Estimate EBITDA	Month EBIT	TEV/ LTM I		<u> </u>	Multiples EBITDA
Clinical Laboratories																					
Laboratory Corporation of America Holdings	\$255.03	25.3%	101.8%	\$259.29	\$110.40	\$24,891	\$6.756	\$1,321	\$30.401	\$13.979	\$3.844	\$3.092	Dec-20	Dec-20	\$14.297	\$3,329	\$2,932	2.2x	7.9x	2.1x	9.1x
Quest Diagnostics Incorporated	128.34	7.7%	59.8%	134.71	73.02	17,128	4,808	1,158	21,157	9,437	2,843	2,182	Dec-20	Dec-20	9,480	2,396	1,886	2.2x	7.4x	2.2x	8.8x
Number of Companies 2	Median:	16.5%	80.8%		Total	\$42,019			\$51,557	\$23,416					\$23,777			2.2x	7.7x	2.2x	9.0x
Market Cap. Weig	hted Average:	18.1%	84.7%															2.2x	7.7x	2.2x	9.0x
Contract Pharma Manufacturing																					
Cleantech Building Materials Plc	\$3.52	0.0%	0.0%	\$0.00	\$0.00	\$257	\$0	\$0	\$257	\$1	(\$3)	(\$5)	Dec-20	Dec-20	NA	NA	NA	NM	NM	NA	NA
West Pharmaceutical Services, Inc.	281.78	(0.5%)	85.1%	312.12	145.78	20,810	331	616	21,012	2,147	564	438	Dec-20	Dec-20	2,554	693	573	9.8x	NM	8.2x	30.3x
Number of Companies 2	Median:	(0.3%)	42.5%		Total	\$21,066			\$21,269	\$2,148					\$2,554			9.8x	#NUM!	8.2x	30.3x
Market Cap. Weig	hted Average:	(0.5%)	84.0%															9.8x	NM	8.2x	30.3x
Contract Research Organizations																					
Catalent, Inc.	\$105.31	1.2%		\$127.68	\$47.01	\$17,927	\$3,060	\$833	\$20,512	\$3,465	\$787	\$516	Dec-20	Jun-20	\$4,127	\$1,086	\$850	5.9x	26.1x	5.0x	18.9x
Charles River Laboratories International, Inc.	289.83	16.0%	129.6%	303.79	116.42	14,552	2,160	229	16,707	2,924	815	541	Dec-20	Dec-20	3,380	835	685	5.7x	20.5x	4.9x	20.0x
ICON Public Limited Company	196.37	0.7%	44.4%	223.62	127.00	10,366	434	842	10,006	2,797	505	409	Dec-20	Dec-20	3,252	588	518	3.6x	19.8x	3.1x	17.0x
Syneos Health, Inc.	75.85	11.3%	92.4%	81.35	32.92	7,837	3,237	272	10,833	4,416	665	357	Dec-20	Dec-20	5,216	764	688	2.5x	16.3x	2.1x	14.2x
PRA Health Sciences, Inc.	153.33	22.2%	84.6%	155.00	71.46	9,897	1,474	506	11,201	3,183	469	284	Dec-20	Dec-20	3,562	597	541	3.5x	23.9x	3.1x	18.8x
IQVIA Holdings Inc.	193.14	7.8%	79.1%	199.99	98.01	37,038	13,238	1,902	49,089	11,359	2,046	817	Dec-20	Dec-20	12,792	2,802	2,404	4.3x	24.0x	3.8x	17.5x
Number of Companies 6	Median:	9.6%	88.5%		Total	\$97,616			\$118,348	\$28,144					\$32,330			3.9x	22.2x	3.5x	18.1x
Market Cap. Weig	hted Average:	8.8%	88.9%															4.5x	22.8x	3.9x	17.9x
Disease Management																					
Tivity Health, Inc.	\$22.32	13.9%	254.8%	\$25.45	\$4.51	\$1.097	\$523	\$100	\$1,521	\$438	\$145	\$132	Dec-20	Dec-20	\$471	\$153	\$135	3.5x	10.5x	3.2x	10.0x
Number of Companies 1	Median:		254.8%	\$23.73	Total	\$1,097	\$323	\$100	\$1,521	\$438	\$173	ψ13Z	Dec-20	Dec-20	\$471	\$133	9133	3.5x	10.5x	3.2x	10.0x
Market Cap. Weig			254.8%		Total	\$1,097			\$1,321	9130					ΦT /1			3.5x	10.5x	3.2x	10.0x
Market cap. Weig	inteu riverage.	13.770	231.070															3.5x	10.54	J.2A	10.01
Healthcare Staffina																					
AMN Healthcare Services, Inc.	\$73.70	8.0%	27.5%	\$80.80	\$36.65	\$3,477	\$955	\$29	\$4,403	\$2,394	\$291	\$166	Dec-20	Dec-20	\$2,789	\$379	\$259	1.8x	15.1x	1.6x	11.6x
Cross Country Healthcare, Inc.	12.49	40.8%	85.3%	13.68	4.50	469	78	2	546	836	38	16	Dec-20	Dec-20	952	47	32	0.7x	14.4x	0.6x	11.6x
ASGN Incorporated	95.44	14.3%	170.2%	102.78	30.15	5,058	1,126	274	5,910	3,951	446	310	Dec-20	Dec-20	4,227	467	349	1.5x	13.3x	1.4x	12.7x
Number of Companies 3	Median:	14.3%	85.3%		Total	\$9,004			\$10,859	\$7,181					\$7,968			1.5x	14.4x	1.4x	11.6x
Market Cap. Weig	hted Average:	13.2%	110.7%															1.6x	14.0x		12.2x

Payor, Provider & Pharmacy Support Services⁽¹⁾

Company Name	3/31/2021	Stock l % Cha		52 V High	Veek Low	Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)		Twelve Mo (LTM) EBITDA	EBIT	LTM Period	Latest FYE Date		d Twelve ! Estimate EBITDA	Month EBIT	TEV/ LTM N		TEV/ Fwd. Revenue	Multiples EBITDA
HMO - Medical																					
Commercial:																					
Anthem, Inc.	358.95	11.8%	58.1%	379.13	199.17	87,909	20,992	30,733	104,204	121,868	9,481	8,260	Dec-20	Dec-20	135,478	9,322	8,525	0.9x	11.0x	0.8x	11.2x
Cigna Corporation	241.74	16.1%	36.4%	248.84	158.84	83,976	33,562	11,500	108,291	160,550	10,940	8,899	Dec-20	Dec-20	165,766	11,093	8,584	0.7x	9.9x	0.7x	9.8x
Humana Inc.	419.25	2.2%	33.5%	474.70	285.49	54,088	7,464	17,227	56,915	77,155	5,522	5,060	Dec-20	Dec-20	81,854	4,258	3,763	0.7x	10.3x	0.7x	13.4x
UnitedHealth Group Incorporated	372.07	6.1%	49.2%	380.50	226.03	351,725	46,258	22,917	392,276	262,916	27,360	24,148	Mar-21	Dec-20	279,206	26,270	23,081	1.5x	14.3x	1.4x	14.9x
Number of Companies 4	Median:	8.9%	42.8%		Total	\$577,698			\$661,687	\$622,489					\$662,304			0.8x	10.6x	0.7x	12.3x
Market Cap. We	ighted Average:	8.1%	47.2%															1.2x	12.8x	1.1x	13.5x
Government:																					
Centene Corporation	\$63.91	6.5%	7.6%	\$74.70	\$53.60	\$37,170	\$18,317	\$12,380	\$44,876	\$104,176	\$5,710	\$4,110	Dec-20		\$117,825	\$5,220	\$4,220	0.4x	7.9x	0.4x	8.6x
Molina Healthcare, Inc.	233.76	9.9%	67.3%	246.72	127.56	13,647	2,440	6,029	12,002	18,375	1,050	972	Dec-20	Dec-20	24,281	1,155	1,045	0.7x	11.4x	0.5x	10.4x
Webcentral Group Limited	0.42	35.8%	596.2%	0.49	0.05	65	43	3	105	40	(10)	(17)	Dec-20	Dec-20	50	6	1	2.6x	NM	2.1x	16.2x
Number of Companies 3	Median:	9.9%	67.3%		Total	\$50,882			\$56,982	\$122,591					\$142,156			0.7x	9.6x	0.5x	10.4x
Market Cap. We	ighted Average:	7.4%	24.4%															0.5x	8.8x	0.4x	9.1x
Information Services																					
Data/Analytics:																					
Castlight Health, Inc.	\$1.51	16.2%	108.8%	\$2.36	\$0.61	\$238	\$15	\$49	\$203	\$147	(\$1)	(\$12)	Dec-20	Dec-20	\$133	\$4	(\$6)	1.4x	NM	1.5x	NM
Inovalon Holdings, Inc.	28.78	58.4%	72.7%	28.88	15.15	4,470	1,034	124	5,386	668	201	75	Dec-20	Dec-20	756	271	119	8.1x	26.9x	7.1x	19.9x
National Research Corporation	46.83	9.5%	3.0%	60.62	40.12	1,190	33	35	1,202	133	50	43	Dec-20	Dec-20	NA	NA	NA	9.0x	23.9x	NA	NA
Number of Companies 3	Median:	16.2%	72.7%		Total	\$5,899			\$1,202	\$948					\$889			8.1x	25.4x	4.3x	19.9x
Market Cap. We	ighted Average:	46.8%	60.1%															8.0x	26.2x	6.8x	19.9x
Hospital/Physician:																					
Allscripts Healthcare Solutions, Inc.	\$15.02	4.0%	113.3%	\$17.96	\$5.28	\$2,103	\$283	\$531	\$1,877	\$1,503	\$43	(\$39)	Dec-20	Dec-20	\$1,503	\$248	\$134	1.2x	NM	1.2x	7.6x
Cerner Corporation	71.88	(8.4%)	14.1%	84.20	59.61	22,016	1,493	1,058	22,587	5,506	1,318	831	Dec-20	Dec-20	5,818	1,873	1,214	4.1x	17.1x	3.9x	12.1x
Computer Programs and Systems, Inc.	30.60	14.0%	37.5%	36.37	19.04	436	83	13	507	264	36	21	Dec-20	Dec-20	274	47	26	1.9x	14.1x	1.9x	10.7x
HMS Holdings Corp.	36.98	0.6%	46.3%	37.22	23.12	3,277	259	207	3,369	673	138	93	Dec-20	Dec-20	737	203	128	5.0x	24.5x	4.6x	16.6x
Premier, Inc.	33.85	(3.6%)	3.5%	37.79	28.64	4,138	612	109	4,650	1,447	484	334	Dec-20	Jun-20	1,573	463	284	3.2x	9.6x	3.0x	10.0x
NextGen Healthcare, Inc.	18.10	(0.8%)	73.4%	23.80	7.84	1,213	71	90	1,204	549	41	19	Dec-20	Mar-20	570	110	31	2.2x	29.2x	2.1x	10.9x
Number of Companies 6	Median:	(0.1%)	41.9%		Total	\$33,183			\$34,193	\$9,943					\$10,475			2.7x	17.1x	2.5x	10.8x
Market Cap. We	ighted Average:	(5.6%)	24.7%															3.8x	17.3x	3.6x	11.9x

Payor, Provider & Pharmacy Support Services⁽¹⁾

Company Name	3/31/20	% Cł	k Price lange 12 mos.		Veek Low	Equity Mkt. Value	Total Debt	Cash and Equiv.	Total Ent. Value (TEV)	Latest Revenue	Twelve Mo (LTM) EBITDA	eBIT	LTM Period	Latest FYE Date		d Twelve ! Estimate EBITDA	Month EBIT	TEV/ LTM	-	TEV/ Fwd.	-
Specialty Managed Care																					
Assurant, Inc.	\$14	1.77 4.19	6 36.2%	\$144.93	\$83.89	\$8,580	\$2,331	\$2,562	\$8,688	\$10,089	\$956	\$784	Dec-20	Dec-20	\$8,747	NA	\$909	0.9x	9.1x	1.0x	NA
CorVel Corporation	10	2.59 (3.29	6) 88.2%	111.42	44.67	1,834	96	129	1,843	554	94	55	Dec-20	Mar-20	NA	NA	NA	3.3x	19.7x	NA	NA
HealthEquity, Inc.	6	8.00 (2.59	6) 34.4%	93.32	40.56	5,645	1,075	329	6,453	734	210	80	Jan-21	Jan-21	756	245	21	8.8x	30.7x	8.5x	26.3x
Number of Companies	3 M e	dian: (2.5%	6) 36.2%		Total	\$16,059			\$16,983	\$11,377					\$9,503			3.3x	19.7x	4.8x	26.3x
Market Cap	p. Weighted Ave	rage: 0.9%	6 41.5%															3.9x	17.9x	4.0x	26.3x
Retail Pharmacy																					
CVS Health Corporation	\$7	5.23 10.19	6 26.8%	\$77.23	\$54.07	\$98,653	\$85,042	\$10,854	\$173,288	\$267,908	\$21,340	\$13,663	Dec-20	Dec-20	\$279,645	\$18,048	\$15,669	0.6x	8.1x	0.6x	9.6x
Walgreens Boots Alliance, Inc.		4.90 37.79	6 20.0%	56.78	33.36	47,455	41,742	1,030	88,990	142,507	7,199	1,654	Feb-21	Aug-20	146,461	7,085	5,524	0.6x	12.4x	0.6x	12.6x
Rite Aid Corporation	2	0.46 29.29	6 36.4%	32.48	8.86	1,130	6,432	161	7,470	24,043	1,262	133	Feb-21	Feb-21	24,261	539	104	0.3x	5.9x	0.3x	13.9x
Number of Companies	3 M e	dian: 29.29	6 26.8%		Total	\$147,238			\$269,748	\$434,458					\$450,367			0.6x	8.1x	0.6x	12.6x
Market Cap	o. Weighted Ave	rage: 19.29	6 24.7%															0.6x	9.5x	0.6x	10.6x

Products & Devices(1)

Commonwell	_		Stock I		FOX	N7 1	Equity Mkt.	Total	Cash and	Total Ent.	Latest '	Twelve Mo	onths	LTM	Latest	Forwar	d Twelve I	Month	TEV/ LTM I	Multiples	TEV/ Fwd.	Multiples
Company Nam		3/31/2021	% Chai	nge 12 mos.	52 V High	Veek Low	Value	Debt	Equiv.	Value (TEV)	Revenue	(LTM) EBITDA	EBIT	Period	FYE Date	Revenue	Estimate EBITDA	EBIT	Revenue	ERITDA	Revenue	EBITDA
Dental Products		2, 22, 2222								(121)												
3M Company		\$192.68	10.2%	41.1%	\$196.72	\$131.01	\$111.642	\$19,775	\$5.045	\$127,726	\$32.184	\$9.427	\$7.067	Dec-20	Dec-20	\$34.377	\$9,406	\$7.492	4.0x	13.5x	3.7x	13.6x
DENTSPLY SIRONA Inc.		63.81	21.9%	64.3%	64.40	35.01	13,977	2,455	471	16,020	3.342	672	271	Dec-20	Dec-20	4.147	973	840	4.8x	23.8x	3.9x	16.5x
Number of Companies	2	Median:	16.1%	52.7%		Total	\$125,620	_,		\$143,747	\$35,526					\$38.524			4.4x	18.7x	3.8x	15.0x
rumber of companies	Market Can We	eighted Average:	11.5%	43.7%		10111	\$125,020			Ψ110,/ 1/	400,020					400,021			4.1x	14.7x	3.7x	13.9x
	- in the cupi we	agareed riverage.	11.070	1017 70																111711	0.7 K	10.7%
Durable Medical Equipment																						
Arjo AB (publ)		\$7.46	3.5%	31.6%	\$8.11	\$5.14	\$2,031	\$755	\$118	\$2,631	\$1,105	\$226	\$116	Dec-20	Dec-20	\$1,034	\$224	\$112	2.4x	11.6x	2.5x	11.8x
Hill-Rom Holdings, Inc.		110.48	12.8%	9.8%	117.68	80.31	7,332	1,907	295	8,966	2,937	588	417	Dec-20	Sep-20	2,917	622	546	3.1x	15.3x	3.1x	14.4x
Invacare Corporation		8.02	(10.4%)	7.9%	10.94	4.91	276	327	105	497	851	35	8	Dec-20	Dec-20	913	44	26	0.6x	14.4x	0.5x	11.2x
ResMed Inc.		194.02	(8.7%)	31.7%	224.43	138.16	28.232	966	256	29.054	3,092	1,025	880	Dec-20	Jun-20	3,307	1,124	927	9.4x	28.3x	8.8x	25.9x
Number of Companies	4	Median:	(2.6%)	20.7%		Total	\$37,871			\$41,148	\$7,985	,			,	\$8,171			2.7x	14.8x	2.8x	13.1x
	Market Cap. We	eighted Average:	(3.9%)	27.3%							. ,								7.7x	24.8x	7.3x	22.8x
			, ,																			
Life Sciences Tools																						
Agilent Technologies, Inc.		\$127.14	7.3%	77.5%	\$136.98	\$68.14	\$38,739	\$2,675	\$1,329	\$40,164	\$5,530	\$1,517	\$1,151	Jan-21	Oct-20	\$6,002	\$1,611	\$1,484	7.3x	26.5x	6.7x	24.9x
Becton, Dickinson and Compar	ny	243.15	(2.8%)	5.8%	284.97	219.50	70,650	17,819	3,265	85,687	18,207	5,438	3,259	Dec-20	Sep-20	19,104	5,403	4,536	4.7x	15.8x	4.5x	15.9x
Thermo Fisher Scientific Inc.		456.38	(2.0%)	60.9%	532.57	270.41	179,719	22,591	10,325	193,373	32,218	10,476	7,878	Dec-20	Dec-20	35,461	11,355	10,581	6.0x	18.5x	5.5x	17.0x
Number of Companies	3	Median:	(2.0%)	60.9%		Total	\$289,108			\$319,224	\$55,955					\$60,568			6.0x	18.5x	5.5x	17.0x
	Market Cap. We	eighted Average:	(1.0%)	49.7%															5.9x	18.9x	5.4x	17.8x
Medical Devices and Products	c																					
Abbott Laboratories	2	\$119.84	9.5%	51.9%	\$128.54	\$75.35	\$212,300	\$19.890	\$7.148	\$227,117	\$34.608	\$9.209	\$5.553	Dec-20	Dec-20	\$42.271	\$12.280	\$10.943	6.6x	24.7x	5.4x	18.5x
Baxter International Inc.		84.34	5.1%	3.9%	95.19	74.79	42.657	6.804	3.730	46.322	11.673	2.870	1.878	Dec-20	Dec-20	12.528	2.952	2.290	4.0x	16.1x	3.7x	15.7x
Boston Scientific Corporation		38.65	7.5%	3.9% 18.4%	42.37	29.65	54,903	9,614	1,734	63,122	9,913	2,870	1,878	Dec-20	Dec-20	11,411	3.312	2,290	4.0x 6.4x	26.9x	5.7x 5.5x	15.7x 19.1x
Conformis, Inc.		0.99	50.0%	57.1%	1.49	0.58	54,903 181	9,614	1,734	185	9,913	(19)	(25)	Dec-20	Dec-20	11,411	(27)	(32)	0.4x 2.7x	26.9X NM	2.7x	19.1x NM
Danaher Corporation		225.08	1.3%	62.6%	248.86	127.70	160,497	22.178	6.035	179,919	22.284	6.741	4.704	Dec-20	Dec-20	26.252	8.104	5.966	2.7x 8.1x	26.7x	6.9x	22.2x
· · · · · · · · · · · · · · · · · · ·		74.38	2.1%	111.9%	85.00	32.00	19,165	2.814	869	21.250	4.536	2.267	1.893	Dec-20	Sep-20	5.262		2,563	8.1x 4.7x	26.7x 9.4x	6.9x 4.0x	8.2x
Hologic, Inc. Johnson & Johnson		74.38 164.35	4.4%	25.3%	173.65	125.50	432,685	36,366	25,425	447.644	4,536 82,584	2,267	20.014	Jec-20 Jan-21	Sep-20 Ian-21	92.025	2,577 32,978	30.044	4./x 5.4x	9.4x 16.3x	4.0x 4.9x	8.2x 13.6x
, ,		118.13	0.8%	31.0%	120.53	81.33	159,248	30,323		176,139	27.926	6.312	3.818	Jan-21 Jan-21	,	32,339	10.012	9.107	6.3x	27.9x	4.9x 5.4x	13.6x 17.6x
Medtronic plc									14,640			0,312	-,-		Apr-20	. ,						
Penumbra, Inc.		270.58 243.58	54.6%	67.7%	314.22	149.23 142.00	9,862	77	265	9,923	560	2.005	(18)	Dec-20	Dec-20	681	52 4.780	29 4.398	17.7x 7.3x	NM	14.6x	NM
Stryker Corporation			(0.6%)	46.3% 41.9%	250.02	142.00 271.99	91,665 19.422	14,425	3,024	104,431	14,351	3,885	2,943	Dec-20	Dec-20	17,076	,	,		26.9x	6.1x	21.8x
Teleflex Incorporated	11	415.46 Median:	0.9% 4.4%	41.9%	434.98	Total	\$1.202.585	2,621	396	21,902	2,537	688	430	Dec-20	Dec-20	2,816	833	761	8.6x 6.4x	31.8x 26.7x	7.8x 5.4x	26.3x 18.5x
Number of Companies		eighted Average:	4.4%	38.3%		Total	\$1,202,585			\$1,297,955	\$211,041					\$242,729			6.4x	26./X 22.2x	5.4x 5.5x	18.5x 17.2x
	market cap. we	eignteu Average:	4.5%	38.3%															0.4x	22.2X	5.5X	17.2X
Medical / Surgical / Dental S	upplies & Distrib	<u>ution</u>																				
AmerisourceBergen Corporati	ion	\$118.07	20.8%	33.4%	\$120.54	\$80.00	\$24,170	\$4,589	\$4,891	\$24,231	\$194,546	\$2,790	\$2,253	Dec-20	Sep-20	\$209,596	\$2,772	\$2,469	0.1x	8.7x	0.1x	8.7x
Cardinal Health, Inc.		60.75	13.4%	26.7%	62.96	44.58	17,840	6,733	3,737	20,840	156,452	2,747	1,894	Dec-20	Jun-20	165,109	2,900	2,509	0.1x	7.6x	0.1x	7.2x
Henry Schein, Inc.		69.24	3.6%	37.1%	74.89	45.95	9,851	1,002	421	11,396	10,119	830	559	Dec-20	Dec-20	11,569	926	734	1.1x	13.7x	1.0x	12.3x
McKesson Corporation		195.04	12.1%	44.2%	198.43	121.15	31,044	9,714	3,577	38,720	237,621	5,041	3,565	Dec-20	Mar-20	249,195	4,837	4,111	0.2x	7.7x	0.2x	8.0x
Owens & Minor, Inc.		37.59	39.0%	310.8%	39.45	5.50	2,763	1,197	83	3,877	8,480	394	241	Dec-20	Dec-20	9,504	454	384	0.5x	9.8x	0.4x	8.5x
Patterson Companies, Inc.		31.95	7.8%	109.0%	36.88	12.93	3,041	795	156	3,689	5,637	356	241	Jan-21	Apr-20	6,067	320	282	0.7x	10.4x	0.6x	11.5x
Number of Companies	6	Median:	12.8%	40.6%		Total	\$88,709			\$102,753	\$612,855			•		\$651,040			0.3x	9.3x	0.3x	8.6x
		eighted Average:	14.5%	47.5%															0.3x	8.8x	0.3x	8.7x

Products & Devices(1)

Company Name	Stock Price % Change			52 W	/eek	Equity Mkt.	Total	Cash and	Total Ent. Value	Latest Twelve Months (LTM)			LTM	Latest		d Twelve ! Estimate	Month	TEV/ LTM	Multiples	TEV/ Fwd. Multiples	
	3/31/2021	3 mos.	12 mos.	High	Low	Value	Debt	Equiv.	(TEV)	Revenue	EBITDA	EBIT	Period	FYE Date	Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
Spec Pharma and Generics																					
Aegon N.V.	\$4.75	25.2%	75.0%	\$5.06	\$2.29	\$9,784	\$17,233	\$28,114	\$16,586	\$59,036	\$688	\$564	Dec-20	Dec-20	\$23,439	NA	\$2,057	0.3x	24.1x	0.7x	NA
Amneal Pharmaceuticals, Inc.	6.73	47.3%	93.4%	7.45	2.71	999	2,997	343	3,714	1,993	407	146	Dec-20	Dec-20	2,138	517	439	1.9x	9.1x	1.7x	7.2x
Eagle Pharmaceuticals, Inc.	41.74	(10.4%)	(9.3%)	56.16	36.48	552	38	103	487	188	38	33	Dec-20	Dec-20	196	56	NA	2.6x	12.9x	2.5x	8.6x
Endo International plc	7.41	3.2%	100.3%	10.89	2.71	1,708	8,396	1,213	8,890	2,903	814	694	Dec-20	Dec-20	2,701	1,234	1,117	3.1x	10.9x	3.3x	7.2x
Horizon Therapeutics Public Limited Company	92.04	25.8%	210.7%	96.54	28.07	20,629	1,051	2,080	20,104	2,200	561	530	Dec-20	Dec-20	2,794	1,047	1,030	9.1x	NM	7.2x	19.2x
Jazz Pharmaceuticals plc	164.37	(0.4%)	64.8%	178.64	95.03	9,258	2,252	2,133	9,601	2,364	1,066	763	Dec-20	Dec-20	2,639	1,212	1,174	4.1x	9.0x	3.6x	7.9x
Lannett Company, Inc.	5.28	(19.0%)	(24.0%)	10.70	4.89	212	629	34	807	543	73	12	Dec-20	Jun-20	476	71	41	1.5x	11.1x	1.7x	11.3x
Minerals Technologies Inc.	75.12	29.0%	106.5%	78.05	35.68	2,549	1,003	372	0	1,595	320	211	Dec-20	Dec-20	1,742	336	241	0.0x	0.0x	0.0x	0.0x
Myanmar Metals Limited	0.05	(26.3%)	79.5%	0.09	0.03	101	0	12	93	0	(7)	(7)	Dec-20	Jun-20	NA	NA	NA	NA	NM	NA	NA
Perrigo Company plc	40.47	(9.5%)	(15.8%)	58.83	38.20	5,405	3,759	644	8,521	5,063	912	479	Dec-20	Dec-20	4,201	682	578	1.7x	9.3x	2.0x	12.5x
Teva Pharmaceutical Industries Limited	11.54	19.6%	28.5%	13.30	7.95	12,654	26,535	2,177	38,047	16,659	4,905	3,193	Dec-20	Dec-20	16,707	5,014	4,433	2.3x	7.8x	2.3x	7.6x
Bausch Health Companies Inc.	31.74	52.6%	104.8%	34.80	12.97	11,289	24,204	605	35,011	8,027	3,236	1,334	Dec-20	Dec-20	8,706	3,460	3,160	4.4x	10.8x	4.0x	10.1x
Number of Companies 12	Median:	11.4%	77.3%		Total	\$75,140			\$141,861	\$100,570					\$65,740			2.3x	10.1x	2.3x	8.3x
Market Cap. We	eighted Average:	22.4%	102.1%															4.3x	11.5x	3.8x	11.9x

Provider-Based Services⁽¹⁾

		Stock				Equity Mkt.	Total	Cash and	Total Ent.	Latest 1	Twelve Months		LTM	Latest	Forward Twelve Month			TEV/ LTM I	Multinles	ΓEV/ Fwd.	Multinles
Company Name	3/31/2021	% Cha	nge 12 mos.	52 V High		Value	Debt	Equiv.	Value	D	(LTM) EBITDA	EBIT		FYE Date		Estimate					
Anuta Cara Hamitala	3/31/2021	5 mos.	12 mos.	nıgn	Low				(TEV)	Revenue	EBITDA	EBH	· ·		Kevenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
Acute-Care Hospitals Community Health Systems, Inc.	\$13.52	82.0%	304.8%	\$14.09	\$2.46	\$1,691	\$12.882	\$1,676	\$13.476	\$11.789	\$1.348	\$586	Dec-20	Dec-20	\$12.083	\$1,665	\$1.124	1.1x	10.0x	1.1x	8.1x
HCA Healthcare, Inc.	188.34	14.5%		194.01	79.74	63,459	33,102	1,909	96,972	51,533	10,900	7,256	Dec-20	Dec-20 Dec-20	54,542	10,652	7,829	1.1x 1.9x	10.0x 8.9x	1.1x 1.8x	9.1x
Tenet Healthcare Corporation	52.00	30.2%	109.6% 261.1%	57.88	11.67	5.537	16.906	2,446	22.881	17.640	2,999	1.739	Dec-20	Dec-20	19,309	2.988	2.132	1.9x 1.3x	7.6x	1.8x 1.2x	7.7x
Number of Companies 3	Median:	30.2%			Total	\$70,686	10,900	2,440	\$133,330	\$80,962	2,999	1,/39	Dec-20	Dec-20	\$85,933	2,988	2,132	1.3x	8.9x	1.2x	8.1x
Market Cap. Wei			126.2%		Total	\$70,080			\$133,330	\$80,962					\$85,955			1.3x 1.8x	8.9x 8.8x	1.7x	9.0x
Market Cap. Wei	gnted Average:	17.4%	126.2%															1.8X	8.8X	1./X	9.0X
Assisted Living																					
Brookdale Senior Living Inc.	\$6.05	36.6%	93.9%	\$6.84	\$2.30	\$1,110	\$5,445	\$553	\$6,004	\$3,023	\$631	\$28	Dec-20	Dec-20	\$3,108	\$197	(\$77)	2.0x	9.5x	1.9x	30.5x
Capital Senior Living Corporation	38.50	212.0%	342.5%	47.79	6.75	79	910	18	971	359	83	(13)	Dec-20	Dec-20	NA	NA	NA	2.7x	11.7x	NA	NA
Number of Companies 2	Median:	124.3%	218.2%		Total	\$1,189			\$6,975	\$3,382					\$3,108			2.3x	10.6x	1.9x	30.5x
Market Cap. Wei	ghted Average:	48.2%	110.4%															2.0x	9.7x	1.9x	30.5x
<u>Long-Term Care</u>																					
National HealthCare Corporation	77.91	17.3%	8.6%	80.51	55.88	1,197	194	323	1,073	978	127	44	Dec-20	Dec-20	NA	NA	NA	1.1x	8.5x	NA	NA
The Ensign Group, Inc.	93.84	28.7%	149.5%	98.66	28.69	5,077	1,114	250	6,208	2,403	419	223	Dec-20	Dec-20	2,654	329	268	2.6x	14.8x	2.3x	18.9x
Number of Companies 2	Median:	23.0%	79.1%		Total	\$6,275			\$7,282	\$3,381					\$2,654			1.8x	11.6x	2.3x	18.9x
Market Cap. Wei	ghted Average:	26.5%	122.6%															2.3x	13.6x	2.3x	18.9x
Diagnostic Imaging																					
RadNet, Inc.	\$21.75	11.1%	106.9%	\$25.49	\$7.92	\$1,137	\$1,185	\$102	\$2,328	\$1.098	\$248	\$53	Dec-20	Dec-20	\$1,225	\$188	\$90	2.1x	9.4x	1.9x	12.4x
Number of Companies 1	Median:	11.1%	106.9%		Total	\$1,137	. ,		\$2,328	\$1,098					\$1,225			2.1x	9.4x	1.9x	12.4x
Market Cap. Wei	ghted Average:		106.9%						. ,	. ,					. ,			2.1x	9.4x	1.9x	12.4x
•																					
Dialysis Services																					
Ariadne Australia Limited	\$0.40	7.1%	19.3%	\$0.42	\$0.29	\$78	\$17	\$24	\$82	\$7	\$4	\$1	Dec-20	Jun-20	NA	NA	NA	12.2x	20.6x	NA	NA
DaVita Inc.	107.77	(8.2%)	41.7%	125.28	64.51	11,790	11,194	345	24,509	11,551	3,040	1,746	Dec-20	Dec-20	11,558	2,416	1,752	2.1x	8.1x	2.1x	10.1x
Fresenius Medical Care AG & Co. KGaA	73.62	(8.0%)	4.2%	93.85	64.77	21,560	15,144	1,542	35,931	21,846	4,875	2,987	Dec-20	Dec-20	21,649	4,500	2,549	1.6x	7.4x	1.7x	8.0x
Number of Companies 3	Median:	(8.0%)			Total	\$33,429			\$60,522	\$33,403					\$33,207			2.1x	8.1x	1.9x	9.1x
Market Cap. Wei	ghted Average:	(8.1%)	15.9%															1.8x	7.6x	1.8x	8.7x
Home Care, Hospice and Home Infusion																					
Home Care / Hospice:																					
Addus HomeCare Corporation	\$104.59	(10.7%)	54.7%	\$129.01	\$62.56	\$1,639	\$240	\$145	\$1,767	\$765	\$73	\$51	Dec-20	Dec-20	\$874	\$91	\$72	2.3x	24.3x	2.0x	19.3x
Amedisys, Inc.	264.79	(9.7%)		325.12	165.42	8,698	307	82	8,967	2.072	288	218	Dec-20	Dec-20	2.304	321	288	4.3x	31.1x	3.9x	27.9x
Chemed Corporation	459.82	(13.7%)		560.00	394.47	7,372	135	163	7,471	2.080	426	315	Dec-20	Dec-20	2,066	423	354	3.6x	17.5x	3.6x	17.7x
LHC Group, Inc.	191.21	(10.4%)		236.81	116.26	6,041	123	287	5,992	2,063	257	180	Dec-20	Dec-20	2,227	276	NA	2.9x	23.3x	2.7x	21.7x
Number of Companies 4	Median:	(10.5%)			Total	\$23,751			\$24,198	\$6,979					\$7,470			3.2x	23.8x	3.2x	20.5x
Market Cap. Wei		(11.2%)				420). 02			42.,270	40,,,,,					4.,			3.6x	24.4x	3.4x	22.6x
Home Infusion:																					
Bioservo Technologies AB (publ)	\$1.72	(13.0%)		\$2.14	\$0.83	\$27	\$0	\$6	\$21	\$2	(\$4)	(\$4)	Dec-20	Dec-20	NA	NA	NA	12.3x	NM	NA	NA
Number of Companies 1	Median:	(13.0%)			Total	\$27			\$21	\$2					\$0			12.3x	NM	NM	NM
Market Cap. Wei	ghted Average:	(13.0%)	103.8%															12.3x	NM	NM	NM

Provider-Based Services⁽¹⁾

Company Name		Stock Price				Equity Mkt.	Total	Cash and	Total Ent.	Latest Twelve Months			LTM	Latest	Forward Twelve Month			TFV/ITM Multiples		s TEV/ Fwd. Multiple	
		% Cha	nge	52 V	Veek	Value	Debt	Equiv.	Value		(LTM)			FYE Date		Estimate		ILV/ EIII	oruntipics	ILV/ I wu.	Multiples
	3/31/2021	3 mos.	12 mos.	High	Low	value	Debt	Equiv.	(TEV)	Revenue	EBITDA	EBIT	1 errou	r i E Date	Revenue	EBITDA	EBIT	Revenue	EBITDA	Revenue	EBITDA
Physician Practice Management																					
Specialty:																					
MEDNAX, Inc.	\$25.47	3.8%	118.8%	\$29.26	\$9.38	\$2,165	\$1,805	\$1,229	\$2,749	\$1,734	\$232	\$174	Dec-20	Dec-20	\$1,768	\$228	\$187	1.6x	11.8x	1.6x	12.1x
Number of Companies 1	Median:	3.8%	118.8%		Total	\$2,165			\$2,749	\$1,734					\$1,768			1.6x	11.8x	1.6x	12.1x
Market Cap. W	Veighted Average:	3.8%	118.8%															1.6x	11.8x	1.6x	12.1x
Behavioral Health / Management																					
Ares Acquisition Corporation	\$9.90	0.0%	0.0%	\$9.96	\$9.50	\$1,205	\$0	\$0	\$1,205	\$0	\$0	\$0	Dec-20	Dec-20	NA	NA	NA	NA	NA	NA	NA
Acadia Healthcare Company, Inc.	57.14	13.7%	211.4%	61.00	15.12	5,109	3,268	379	8,083	2,090	465	333	Dec-20	Dec-20	2,263	527	390	3.9x	17.4x	3.6x	15.3x
Civitas Solutions, Inc.	0.00	0.0%	0.0%	0.00	0.00	0	706	10	0	1,613	173	83	Dec-18	Sep-18	NA	NA	NA	0.0x	0.0x	NA	NA
Magellan Health, Inc.	93.24	12.6%	93.8%	95.43	40.02	2,421	678	1,147	2,003	4,578	97	22	Dec-20	Dec-20	4,680	213	121	0.4x	20.7x	0.4x	9.4x
Universal Health Services, Inc.	133.39	(3.0%)	34.6%	143.84	83.28	11,350	4,194	1,224	14,606	11,559	1,987	1,360	Dec-20	Dec-20	12,176	1,810	1,274	1.3x	7.4x	1.2x	8.1x
Number of Companies 5	Median:	0.0%	34.6%		Total	\$20,085			\$25,899	\$19,840					\$19,118			0.9x	12.4x	1.2x	9.4x
Market Cap. W	Veighted Average:	3.3%	84.6%															1.9x	11.8x	1.7x	10.2x
Surgicenters / Rehabilitation																					
Surgery Centers(*):																					
Surgery Partners, Inc.	\$44.26	52.6%	577.8%	\$44.98	\$4.75	\$2,585	\$3,258	\$318	\$7,120	\$1,860	\$386	\$200	Dec-20	Dec-20	\$2,204	\$316	\$280	3.8x	18.4x	3.2x	22.5x
Number of Companies 1	Median:	52.6%	577.8%		Total	\$2,585			\$7,120	\$1,860					\$2,204			3.8x	18.4x	3.2x	22.5x
Market Cap. W	Veighted Average:	52.6%	577.8%															3.8x	18.4x	3.2x	22.5x
Rehabilitation:																					
Encompass Health Corporation	\$81.90	(1.0%)	27.9%	\$88.42	\$58.79	\$8.130	\$3,543	\$224	\$11.882	\$4.644	\$972	\$651	Dec-20	Dec-20	\$5.064	\$946	\$705	2.6x	12.2x	2.3x	12.6x
Select Medical Holdings Corporation	34.10	23.3%	127.3%	37.42	11.92	4,598	4.501	577	9.112	5.532	1.039	507	Dec-20	Dec-20	5.753	850	631	1.6x	8.8x	1.6x	10.7x
U.S. Physical Therapy, Inc.	104.10	(13.4%)	50.9%	143.67	53.81	1,343	125	33	1.569	418	105	56	Dec-20	Dec-20	470	64	64	3.7x	15.0x	3.3x	24.6x
Number of Companies 3	Median:	(1.0%)	50.9%	1.5.07	Total	\$14.070	123	33	\$22,563	\$10.594	103	30	200 20	200 20	\$11.287	01	01	2.6x	12.2x	2.3x	12.6x
	Veighted Average:	5.8%	62.6%		10111	Ψ11,070			Ψ22,303	Ψ10,377					Ψ11,207			2.4x	11.4x	2.2x	13.1x
market cap. v	cignica Average.	3.0 70	02.070															4.TA	11.77	2.21	13.11

Our Firm

Harris Williams has a broad range of industry expertise, which creates powerful opportunities. Our clients benefit from our deep-sector experience, integrated industry intelligence and collaboration across the firm, and our commitment to learning what makes them unique. For more information, visit our website at www.harriswilliams.com/industries.

Aerospace, Defense& GovernmentServices



Building Products& Materials



BusinessServices



Consumer



Energy, Power& Infrastructure



HARRIS WILLIAMS OFFICE

UNITED STATES

B O S T O N One International Place Suite 2620 Boston, Massachusetts 02110 Phone: +1 (617) 482-7501 C L E V E L A N D

LOCATIONS

1900 East 9th Street 20th Floor Cleveland, Ohio 44114 Phone: +1 (216) 689-2400

M I N N E A P O L I S 222 South 9th Street Suite 3350 Minneapolis, Minnesota 55402 Phone: +1 (612) 359-2700 (H E A D Q U A R T E R S) 1001 Haxall Point 9th Floor Richmond, Virginia 23219 Phone: +1 (804) 648-0072

RICHMOND

S A N F R A N C I S C O One Market Plaza 11th Floor San Francisco, CA 94105

W A S H I N G T O N , D . C . 800 17th St. NW 2nd Floor Washington, D.C. 20006 Phone: +1 202-207-2300

Healthcare& Life Sciences



Industrials



Specialty Distribution



Technology



Transportation & Logistics



UNITED STATES

F R A N K F U R T Bockenheimer Landstrasse 33-35 60325 Frankfurt Germany Phone: 449 069 3650638 00

L O N D O N 25 Savile Row 4th Floor London W15 2ER, England Phone: +44 (0) 20 7518 8900

HW Harris Williams / GLOBAL M&A ADVISOR

3 DECADES

10 INDUSTY GROUPS

With Robust Experience Across the Globe

of Providing Award-Winning M&A Advisory Services

1 UNIFIED TEAM

Bringing Firmwide Dedication to Every Engagement

- > Aerospace, Defense & Government Services
- > Building Products & Materials
- > Business Services
- > Consumer
- > Energy, Power & Infrastructure
- > Healthcare & Life Sciences
- > Industrials
- Specialty Distribution
- > Technology
- > Transportation & Logistics

COLLABORATIVE EFFORTS IN THE SPACE

Our Healthcare & Life Sciences Group has a strong track record collaborating to advise leading healthcare companies worldwide.

Turner Bredrup | Senior Advisor 804.915.0110 tbredrup@harriswilliams.com

James Clark | Managing Director 804.915.0119 jclark@harriswilliams.com

Andy Dixon | Managing Director 415.217.3419

adixon@harriswilliams.com

Paul Hepper | Managing Director 804.932.1326 phepper@harriswilliams.com

Whit Knier | Managing Director 804.932.1321 wknier@harriswilliams.com

Cheairs Porter | Managing Director 804.915.0130 cporter@harriswilliams.com

Geoff Smith | Managing Director 804.915.0195 gsmith@harriswilliams.com

RECENT HEALTHCARE AND LIFE SCIENCES DEALS









Harris Williams

SOURCES

- 1. S&P
- 2. PNC Debt Capital Markets
- 3. Company Filings

DISCLOSURES AND DISCLAIMERS

Investment banking services are provided by Harris Williams LLC ("Harris Williams"). Harris Williams is a registered broker-dealer and member of FINRA and SIPC. Harris Williams & Co. Ltd is a private limited company incorporated under English law with its registered office at 8th Floor, 20 Farringdon Street, London EC4A 4AB, UK, registered with the Registrar of Companies for England and Wales, registration number 07078852. Harris Williams & Co. Ltd is authorized and regulated by the Financial Conduct Authority. Harris Williams & Co. Corporate Finance Advisors GmbH is registered in the commercial register of the local court of Frankfurt am Main, Germany, under HRB 107540. The registered address is Bockenheimer Landstrasse 33-35, 60325 Frankfurt am Main, Germany (email address: hwgermany@harriswilliams.com). Geschäftsführers/Directors: Jeffery H. Perkins, Paul Poggi, VAT No. DE321666994. Harris Williams is a trade name under which Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.

The information and views contained in this content have been prepared in part by Harris Williams. This content does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate any investment or potential transaction. This content is not a research report, as such term is defined by applicable law and regulations, and is provided for informational purposes only. Any and all information, including estimates, projections and other forward-looking statements, presented in this document may involve various assumptions and significant elements of subjective judgment and analysis that may or may not be correct. Harris Williams has not independently verified, and neither Harris Williams nor any other person will independently verify, any of the information, estimates, projections or forward-looking statements contained herein or the assumptions on which they are based. The information contained in this document is made as of the date hereof unless stated otherwise. Harris Williams does not expect to update or otherwise revise this document nor provide any additional information, nor correct any inaccuracies herein which may become apparent.

This content is intended for institutional use only and should not be relied upon by retail investors or members of the general public. The information contained herein is believed by Harris Williams to be reliable, but Harris Williams makes no representation or warranty as to the accuracy or completeness of such information, and information contained herein that is based on material prepared by others may involve significant elements of subjective judgment and analysis which may or may not be correct. Opinions, estimates and projections contained herein constitute Harris Williams' judgment and are subject to change without notice.

This content is not to be construed as investment advice an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular transaction, nor shall this content form the basis of any contract. It does not constitute and should not be construed as an endorsement or recommendation of any entities' products or services.

No part of this material may be copied or duplicated in any form or by any means, or redistributed, without Harris Williams' prior written consent.